Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Dermatology
    • Solithromycin not...

    Solithromycin not effective alternative to standard gonorrhea treatment: Lancet

    Written by Hina Zahid Published On 2019-06-14T19:15:28+05:30  |  Updated On 14 Jun 2019 7:15 PM IST
    Solithromycin not effective alternative to standard gonorrhea treatment: Lancet

    Solithromycin isn't a suitable alternative to standard therapy of ceftriaxone plus azithromycin for treating gonorrhea, finds a new study.It is a novel fourth-generation macrolide undergoing clinical development for the treatment of community-acquired pneumonia and other infections.Given growing concerns about antibiotic-resistant Neisseria gonorrhoeae, scientists are looking for new therapies.The study appeared in The Lancet Infectious Diseases.


    Antibiotic-resistance in gonorrhoea represents a global public health threat, and new therapies are needed. The researchers from Australia and the United States aimed to compare the efficacy and safety of solithromycin, a fourth generation macrolide, with ceftriaxone plus azithromycin for the treatment of gonorrhoea.


    The researchers conducted an open-label, multicentre, non-inferiority trial of patients aged 15 years or older with uncomplicated untreated genital gonorrhoea at two sites in Australia and one site in the USA from September 2014 through August 2015. Patients with gonorrhea ages 15 and older were randomly assigned to receive a single 1,000-milligram (mg) dose of solithromycin or a 500-mg intramuscular dose of ceftriaxone plus a 1,000-mg dose of azithromycin. Of 261 participants, 130 were in the solithromycin group and 131 were in the standard-treatment group. Researchers also obtained Neisseria gonorrhoeae cultures at baseline and test day of cure.


    Of patients in the solithromycin group, 80% showed evidence of cure on follow-up testing, compared with 84% of the standard-treatment group, suggesting that solithromycin did not show non-inferiority at the preset -10% criterion.


    A secondary analysis limited to patients who had follow-up testing found that the eradication rate for solithromycin was 92%, compared with 100% for standard therapy. Also, the team found that adverse events such as diarrhea and nausea were higher in the solithromycin group.


    The authors concluded that the solithromycin dose tested isn't a suitable alternative first-line treatment, and further trials of longer dosing will need to consider potential side-effect risks. Solithromycin as a single 1000 mg dose is not a suitable alternative to ceftriaxone plus azithromycin as first-line treatment for gonorrhoea. If the insufficient duration of solithromycin exposure at the infection site in a subset of individuals was the reason for treatment failures, this might be adequately addressed with dose adjustment.


    They note that the study found that solithromycin treatment failures weren't due to reinfection, hinting that a single dose might not be sufficient. They wrote that more study is needed on the pharmacodynamics of solithromycin. They add that the novel drug's use might be threatened by emerging azithromycin-resistant gonorrhoea strains and that future trials involving the drug should include azithromycin-resistant gonorrhea strains.


    For further reference log on to :

    DOI:https://doi.org/10.1016/S1473-3099(19)30116-1

    ceftriaxone plus azithromycindiarrheaGonorrheagonorrhea treatmentgonorrhoeaHenry de Vriesintramuscular doseN gonorrhoeaenauseaNeisseria gonorrhoeaepharmacodynamicssingle dosesolithromycinstrains.The Lancet Infectious Diseases

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Hina Zahid
    Hina Zahid
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok